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Background: Recurrent aphthous stomatitis (RAS) appears to be the most common type of oral ulcers. The 
lesion is usually self limited but its painful presentation results in some difficulties. Therefore, an efficient thera-
peutic strategy is required and currently existing therapies seem to be inadequate because of its unclear etiology. 
Here the therapeutic effect of triamcinolone acetonide ointment as a relatively expensive medication has been 
compared with phenytoin syrup on aphthous ulcers in patients with Behcet’s syndrome.  
 
Methods: Thirty out of 60 our patients with Behcet’s syndrome were randomly treated by phenytoin syrup and 
the remaining  were advised to use 0.1% triamcinolone acetonide ointment. After a week, they were visited again 
to determine the status of aphthous ulcers.  
 
Result: Positive response in the triamcinolone acetonide  group and phenytoin  group was 86.7% and 53.3%, 
respectively. 
 
Conclusion: The effectiveness of triamcinolone acetonide ointment was more than  phenytoin on aphthous 
ulcers in patients with Behcet’s syndrome. 
 





Recurrent aphthous stomatitis (RAS) appears to be 
the most common type of oral ulcers. Typically it is 
presented as self limited ulcers affecting non-
keratinized oral mucosa.
1 The first lesions often ap-
pear when the patient is a child.
2 It has a higher 
prevalence in younger adults and the incidence and 
severity would decrease with age.
3-7 No gender predi-
lection has been detected.
3 
Minor, major and herpetiform aphthous ulcers are 
the subdivisions. Minor ones, seen in 80% of patients
8-
10 are less than 10 mm in diameter. The round or ovoid 
ulcers with a pseudo membranous base surrounded by 
erythema, often appear on labial or buccal mucosa, 
heal within 7-10 days and leave no scar.
1,2,8,11 
Major aphthous ulcers are presented as larger and 
deeper ulcers, mostly seen on soft palate, tonsils, 
tongue or pharynx, heal within several weeks and 
usually leave scar. Herpetiform aphthous usually pre-
sent as ulcers of 1-3 mm in diameter and occur in 
groups. They heal within 1-4 weeks.
1,2,8,12-17 
The cause of RAS is still unknown, although there 
are many promoting and exacerbating factors such as 
positive family history, trauma, nutritional deficiency 
(iron, vitamin B12, folate), food hypersensitivity, 
immune disturbance, smoking cessation and psycho-
logical stress.
1,2,8,12-16 RAS generally is not associated 
with systemic disorders but aphthous like ulcers may 
be the presentation of some disorders such as 
Behcet’s and Reiter’s syndrome.
2,17 
Although the lesion is usually self limited, its 
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speaking and swallowing and decreased quality of 
life. Patients may suffer from its high frequency, too.
1 
So an efficient therapeutic strategy is needed and be-
cause of its unclear etiology, current available thera-
pies seem to be inadequate.
1,13 
The therapeutic strategies for minor aphthous le-
sions include concurrent oral hygiene, coating agents, 
antiseptics, antibiotics, hormones, topical anesthesia 
and steroids. These methods mostly relieve symptoms 
and accelerate healing but systemic ones, although 
effective, have side effects. Therefore, topical thera-
pies are the first choice.
8 Here, we are to compare the 
therapeutic effect of triamcinolone acetonide oint-
ment as a relatively expensive and not easily availa-
ble medication in Iran, with phenytoin syrup on aph-
thous  ulcers  in patients with Behcet’s syndrome. 
Triamcinolone acetonide is a fluoride synthetic 
corticosteroid. Its cream (0.1%) and ointment (0.1%) 
forms are available for topical use. The absorption 
rate varies from 1% in palms and knee to 36% in 
face, eyelash and genital area. Its absorption increases 
via damaged, inflammed or dressed skin. Steroids 
may have systemic absorption via oral mucosa.
18 
Metabolism of triamcinolone after topical applica-
tion is dermal. The small amount which may enter 
systemic circulation is metabolized in liver. Topical 
application’s side effects are burning, itching, irrita-
tion, dryness, folliculitis, hirsutism, hyperpigmenta-
tion, perioral dermatitis, contact allergic dermatitis, 
secondary infections and atrophy.
18 
Phenytoin was first made in 1908 and its anticon-
valescent effect was detected in 1938. The most 
common side effect of phenytoin is gingival hyper-
plasia. These effects were reported in 1939.
19 Dill and 
Iacopino reported a case of skin thickening due to 
long term application of phenytoin. Thickening oc-
curred in face and Talon which revealed the prolifera-
tive effect of the medication on connective tissue 
cells in whole body.
20 
In an animal study, the angiogenesis effect of 
phenytoin was shown. It also led to decreased in-
flammation and bacterial colonies, necrosis and pro-
liferation of fibroblasts.
21 Phenytoin affected epitheli-
um via keratinocyte growth factors and their receptors 
which may have a significant role on wound healing. 
Ghapanchi et al. applied phenytoin powder on wound 
secondary to flap and reported less edema and in-
flammation and more granulation tissue and fibrosis. 
It also led to less pain and burning sensation and ac-
celerated wound healing clinically.
22 Phenytoin can 
be used as syrup (125 mg/5 ml), ampule (250 mg/5 
ml), cream (1%) and capsule (50 and 100 mg) . The 
classic form of topical application is suspension (30 
mg/5 ml).
23 
In this study, the therapeutic effect of triamcino-
lone acetonide ointment as a relatively expensive 
medication was compared with phenytoin syrup on 
aphthous ulcers in patients with Behcet’s syndrome. 
 
 
Materials and Methods 
 
Sixty patients with Behcet’s Syndrome who had 
oral aphthous lesions were assessed for eligibility 
to participate in this trial (IRCT code: 
IRCT201107036920N2). It was their first visit and did 
not have any medication for the disease. All were vis-
ited by a rheumatologist and a dentist. They all an-
swered a questionnaire about demographic data, the 
age of Behcet’s syndrome onset, the most affected 
oral site with the aphthous ulcers, duration of ulcers 
and severity of pain and burning. Then the dentist 
visited them and recorded the site of aphthous lesions, 
their size and number. 
Thirty patients were randomly selected and treated 
by phenytoin syrup and other 30 ones were advised to 
use 0.1% triamcinolone acetonide ointment. Those in 
triamcinolone group applied the ointment three times 
a day on the lesions and had been advised not to have 
water or meal till 30 minutes. Those in phenytoin 
group used 2 teaspoon of syrup in half a glass of 
warm water as mouthwash for 4-5 minutes, three 
times a day and had been advised not to have water or 
meal till 30 minutes. After a week, they were visited 
again to determine the status of aphthous ulcers.  
In this study, the group treating by triamcinolone 
was named “ T” and the other named “P”. The 
statistical analysis was performed using SPSS 
software (Version 14.0, Chicago, IL, USA). We used 
Fisher’s Exact test and Independent t test to compare 
positive response of the groups and the mean of 





There were 8 men and 22 women in each group 
(Table 1). The mean age in “T” group was 
35.47+8.85 years and in “P” group was 38.77+9.4 
years (Table 1). So the mean age and gender in these 
two groups were almost equal and could not interfere 
in the results (p>0.05). Among 30 patients in “T” Phenytoin and triamcinolone in aphthous 
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group, 4 of them (13.3%) did not respond to the 
medication and 26 of them (86.7%) had a positive 
response. In “p” group, 14 of them (46.7%) did not 
respond to the medication and 16 of them (53.3%) 
had a positive response. Statistical tests revealed that 
triamcinolone ointment had a better therapeutic effect 





Aphthous ulcer is the chief complain of a significant 
percentage of patients visited by physicians or dentists. 
It sometimes interferes with patients’ activities and 
decreases their quality of life because of severe pain 
and burning. Some specialists have immunomodulative 
strategy. Brown and Bott applied combination of 
azathioprine and dexamethasone on aphthous ulcers, 
topically and had a good result.
24 Miles and Steven 
revealed that triamcinolone acetonide is a useful 
medication for aphthous lesion.
24 This is similar to our 
findings which shows that corticosteroids are effective 
in treatment of aphthous lesions. 
In an animal study, Ghapanchi and colleagues applied 
phenytoin powder on wound secondary to flap and 
reported less edema and inflammation and more granu-
lation tissue and fibrosis. It also led to less pain and 
burning sensation and clinically an accelerated wound 
healing.
22 In our study, healing of most aphthous ulcers 
with phenytoin application resembled their results. 
There was not any study to compare the effect of these 
tow medications. In our study, the positive response to 
triamcinolone acetonide (86.7%) was more than phen-
ytoin (53.3%) (p<0.05). So it is not logical to replace 
phenytoin instead of triamcinolone; although triamcin-
olone ointment is more expensive and less available. 
Triamcinolone acetonide ointment was shown to be 
more effective than phenytoin on aphthous ulcers in 
patients with Behcet’s syndrome. 
 
 










1  Gallo Cde B, Mimura MA, Sugaya 
NN. Psychological stress and 
recurrent aphthous stomatitis. 
Clinics (Sao Paulo) 2009;64:645-8. 
[19606240] 
2  Keogan MT. Clinical Immunology 
Review Series: an approach to the 
patient with recurrent orogenital 
ulceration, including Behçet's 
syndrome. Clin Exp Immunol 2009; 
156:1-11. [19210521] [http://dx.doi.org/ 
10.1111/j.1365-2249.2008.03857.x] 
3  Mimura MA, Hirota SK, Sugaya NN, 
Sanches Jr JA, Migliari DA. Systemic 
treatments in severe cases of 
recurrent aphthous stomatitis: an 
open trial. Clinics (Sao Paulo) 
2009;64:193-8. [19330244] [http:// 
dx.doi.org/10.1590/S1807-5932200 
9000300008] 
4  Vincent SD, Lilly GE. Clinical, 
historic and therapeutic features of 
aphthous stomatitis. Literature 
review and open clinical trial 
employing steroids. Oral Surg Oral 
Med Oral Pathol 1992;74:79-86. 
[1508514] [http://dx.doi.org/10.1016/ 
0030-4220(92)90219-G] 
5  Natah SS, Konttinen YT, Enattah 
NS, Ashammakhi N, Sharkey KA, 
Häyrinen-Immonen R. Recurrent 
aphthous ulcers today: a review of 
the growing knowledge. Int J Oral 
Maxillofac Surg 2004;33:221-34. 
[15287304] [http://dx.doi.org/10. 
1006/ijom.2002.0446] 
6  Reichart PA. Oral mucosal lesions 
in a representative cross-sectional 
study of aging Germans. Community 
Dent Oral Epidemiol 2000;28:390-8. 
[11014516] [http://dx.doi.org/10.10 
34/j.1600-0528.2000.028005390.x] 
7  Kleinman DV, Swango PA, Niessen 
LC. Epidemiologic studies of oral 
mucosal conditions--methodologic 
issues.  Community Dent Oral 
Epidemiol 1991;19:129-40. [186406 
4] [http://dx.doi.org/10.1111/j.1600-
0528.1991.tb00128.x] 
8  Meng W, Dong Y, Liu J, Wang Z, 
Zhong X, Chen R , Zhou H, Lin M, 
Jiang L, Gao F, Xu T, Chen Q, Zeng 
X. A clinical evaluation of 
ameloxanox oral adhesive pellicles 
in the treatment of recurrent 
aphthous stomatitis and comparison 
with ameloxanox oral tablets: a 
randomized, placebo controlled, 
blinded, multicenter clinical trial. Bio 
Med Central. http://www.trialsjournal. 
com/content/10/1/30. ( 6 May 2009) 
9  Barrons RW. Treatment strategies 
for recurrent oral aphthous ulcers. 
Am J Health Syst Pharm 2001; 
58:41-5. [11194135] 
Table 1: The demographic characteristics of patients treated with phenytoin (P group) and triamcinolone ace-
tonide (T group) 
a. 
 
  Sex Age (years) 
Men Women Min Max Mean+-SD
P group  8 (26.7%)  22 (73.3%)  17  65  38.77+-9.4 
T group  8 (26.7%)  22 (73.3%)  15  57  35.47+-8.85 
a  p=0.167 Fani et al. 
 
WWW.ircmj.com Vol 14 February 2012  78
10  Akintoye SO, Greenberg MS. 
Recurrent aphthous stomatitis. Dent 
Clin North Am 2005;49:31-47, vii-
viii. [15567359] [http://dx.doi.org/ 
10.1016/j.cden.2004.08.001] 
11  Femiano F, Lanza A, Buonaiuto C, 
Gombos F, Nunziata M, Piccolo S, 
Cirillo N. Guidelines for diagnosis 
and management of aphthous 
stomatitis. Pediatr Infect Dis J 2007; 
26:728-32. [17848886] [http://dx. 
doi.org/10.1097/INF.0b013e318062
15f9] 
12  Woo SB, Sonis ST. Recurrent 
aphthous ulcers: a review of 
diagnosis and treatment. J Am Dent 
Assoc 1996;127:1202-13. [8803396] 
13  Ship JA, Chavez EM, Doerr PA, 
Henson BS, Sarmadi M. Recurrent 
aphthous stomatitis. Quintessence 
Int 2000;31:95-112. [11203919] 
14  Casiglia JM. Recurrent aphthous 
stomatitis: etiology, diagnosis, and 
treatment.  Gen Dent 2002;50:157-
66. [12004710] 
15  Scully C, Gorsky M, Lozada-Nur F. 
The diagnosis and management of 
recurrent aphthous stomatitis: a 
consensus approach. J Am Dent 
Assoc 2003;134:200-7. [12636124] 
16  Natah SS, Konttinen YT, Enattah 
NS, Ashammakhi N, Sharkey KA, 
Häyrinen-Immonen R. Recurrent 
aphthous ulcers today: a review of 
the growing knowledge. Int J Oral 
Maxillofac Surg 2004;33:221-34. [152 
87304] [http://dx.doi.org/10.1006/ 
ijom.2002.0446] 
17  Scully C. Aphthous ulceration. N 
Engl J Med 2006;355:165-72. [1683 
7680] [http://dx.doi.org/10.1056/NE 
JMcp054630] 
18  Khandwala A, Van Inwegen RG, 
Alfano MC. 5% amlexanox oral 
paste, a new treatment for recurrent 
minor aphthous ulcers: I. Clinical 
demonstration of acceleration of 
healing and resolution of pain. Oral 
Surg Oral Med Oral Pathol Oral 
Radiol Endod 1997;83:222-30. [91 
17754] [http://dx.doi.org/10.1016/ 
S1079-2104(97)90009-3] 
19  Laurence L. Brunton, John S. Lazo, 
Keith L. Parker. Drugs Acting on the 
central nervous system in: Goodman 
& Gilman’s The pharmacological 
basis of therapeutics. 11
th ed. New 
York, Chicago, San Francisco, 2006: 
p. 508-10. 
 
20  Dill RE, Iacopino AM. Myofibroblasts 
in phenytoin-induced hyperplastic 
connective tissue in the rat and in 
human gingival overgrowth. J 
Periodontol 1997;68:375-80. [915 
0043] 
21  Vernillo AT, Schwartz NB. The effects 
of phenytoin (5,5-diphenylhydantoin) 
on human gingival fibroblasts in 
culture.  J Periodontal Res 1987; 
22:307-12. [2957484] [http://dx.doi. 
org/10.1111/j.1600-0765.1987.tb01 
590.x] 
22  Ghapanchi J,Haghighati F, Dehpoor 
GH. The reparative effect of 
Phenytoin on ulcers secondary to 
gingival surgery. Journal of Dentistry 
1999;131-35. [Persian]  
23  Saber M.Iranian generic medication 
and classification of them. 1th ed. 
Iran, Tehran,  Noore Danesh; 2002. 
24  Miles DA, Bricker SL, Razmus TF, 
Potter RH. Triamcinolone acetonide 
versus chlorhexidine for treatment of 
recurrent aphthous stomatitis. Oral 
Surg Oral Med Oral Pathol 1993;75: 
397-402. [8469556] [http://dx.doi.org/ 
10.1016/0030-4220(93)90158-Z] 
 